The Institute of Cancer Research

Cancer cell
#Biomarkers #Breast cancer #Cancer research #Genetics / genomics #Oncology #Personalised medicine #The Institute of Cancer Research

Genetic biomarkers could personalise therapy for TNBC

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. The study, by researchers at The Institute of Cancer Research, London, shows that certain characteristics within patients’ primary tumours… Read More

#Cancer Research #News #Trending News

Breast cancer cell
#Cancer research #Gene mutation #Oncology #PARP inhibitors #The Institute of Cancer Research

PARP inhibitor use could be extended to more cancer patients

New findings suggest PARP inhibitor drugs, used to treat cancer patients who have an altered BRCA1 or BRCA2 gene, may also be effective for patients which have changes in the SF3B1 gene. If further research supports these findings, there is the potential that existing PARP inhibitor… Read More

#Cancer Research #Editor's Choice #News

Kaposi Sarcoma
#Cancer research #Immunotherapy #Oncology #Proteomics #The Institute of Cancer Research

Sarcoma ‘Rosetta stone’ could bring new era of personalisation

Scientists have unveiled the first and largest encyclopaedia of protein alterations in soft tissue sarcomas – opening the door to a new era of understanding and treatment for this group of rare cancers. The pioneering encyclopaedia, or ‘Rosetta Stone’, of sarcoma biology compiles a wealth of… Read More

#Cancer Research #Editor's Choice #News

#Artificial intelligence (AI) #Cancer research #Collaboration #Oncology #Precision medicine #The Institute of Cancer Research #Vivan Therapeutics

AI discovery collaboration targets precision cancer drugs

Researchers will combine expertise in drug discovery, artificial intelligence (AI), and experimental cancer models and platforms in a new programme to design the precision cancer drugs of the future. Under an academic and commercial collaboration between The Institute of Cancer Research, London, the Bellvitge Biomedical Research… Read More

#Cancer Research #News

Cancer research lab
#American Society of Clinical Oncology #ASCO #Cancer research #Oncology #Phase II trial #The Institute of Cancer Research #The Royal Marsden NHS Foundation Trust

New drug combination twice as effective for some ovarian cancer patients

A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as effective as the next best treatment, according to interim results from a Phase II study. Researchers hope these results, which were presented at the 2023 American Society of Clinical… Read More

#Cancer Research #News

Pancreatic cancer
#Cancer research #Oncology #Pancreatic cancer #The Institute of Cancer Research #University of Michigan

Uridine discovery could lead to new pancreatic cancer therapies

Pancreatic cancer cells can change their ‘diet’ to keep growing, by switching from the sugar glucose to a back-up fuel called uridine, new research has revealed. The findings suggest that blocking the availability of uridine using new drugs could become a new treatment strategy for the… Read More

#Cancer Research #News

Institute of Cancer Research
#Algok Bio #Cancer research #Oncology #Phase II trial #The Institute of Cancer Research

Ovarian cancer drug enters Phase II trials

An ovarian cancer drug, which targets the alpha folate receptor (FRα), is set to enter Phase II trials. Idetrexed (formerly known as BTG945, ONX-0901 and CT900) was created by scientific teams in what is now The Institute of Cancer Research (ICR) Centre for Cancer Drug Discovery,… Read More

#Cancer Research #News

Human breast cancer cells stained for DNA
#Cancer research #Collaboration #DNA #NeoPhore #Oncology #Partnership #The Institute of Cancer Research

Immuno-oncology collaboration to develop new type of cancer drug

Scientists at The Institute of Cancer Research, London, are teaming up with small molecule neoantigen immuno-oncology company NeoPhore to develop new potential cancer drugs. Under a new strategic research collaboration, an ICR team led by Professor Chris Lord will investigate the effect of NeoPhore’s inhibitors on tumours in the laboratory. Read More

#Business & Investment #News

Cancer research in laboratory
#AstraZeneca #Breast cancer #Cancer research #National Institute for Health and Care Excellence (NICE) #Oncology #Prostate cancer #The Institute of Cancer Research #UK

NICE approves olaparib for early-stage breast cancer and prostate cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended that Lynparza (olaparib) can be used for NHS patients with both early-stage breast cancer and prostate cancer. Olaparib is PARP inhibitor that targets cancers linked to faulty BRCA1 or BRCA2 genes and works across many different cancer types. The… Read More

#News #Regulatory #Trending News

Cancer research
#Animal models #Cancer research #Cancer treatment #Oncology #The Institute of Cancer Research

First-in-class HSF1 pathway drug shrinks tumours in mice

A new, oral, first-in-class experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows. The drug, which is now called NXP800 and has already entered a Phase I clinical trial, was… Read More

#Cancer Research #News

Research in genetics laboratory
#Cancer research #Epigenetics #Gene expression #Genetics / genomics #Oncology #The Institute of Cancer Research

Epigenetics discovery could lead to new class of cancer drugs

A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs.  Epigenetics is still largely unexplored and referred to as the ‘dark matter’… Read More

#Cancer Research #Editor's Choice #News

Patient using a mammography machine
#AstraZeneca #Breast cancer #Cancer research #Phase III trial #Precision medicine #The Institute of Cancer Research

Targeted breast cancer drug extends lives of patients in Phase III trial

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major Phase III clinical trial.  The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most… Read More

#Cancer Research #News #Trending News

X-ray showing colon cancer
#Bowel cancer #Cancer research #Cryo-EM #cryo-microscopy #The Institute of Cancer Research

Bowel cancer protein study could lead to less toxic cancer drugs

Scientists have revealed the inner workings of a key protein involved in a wide range of cellular processes – potentially paving the way for better and less toxic cancer drugs.  Using Nobel Prize-winning microscopy techniques, the researchers revealed how the tankyrase protein switches itself on and off… Read More

#Cancer Research #News

#AI #Cancer #Cancer drug targets #Cancer immunotherapy #Cancer research #Immunotherapy #Oncology #The Institute of Cancer Research #The Royal Marsden NHS Foundation Trust

Scientists will target cancer’s ecosystems under new strategy

Cancer is supported by complex ecosystems within the body which can be disrupted by cutting-edge new treatments and cures, cancer researchers have concluded.  The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have revealed plans to direct research against the cells, signals and… Read More

#Cancer Research #News

Stomach cancer cells
#ATR inhibitors #Cancer #Cancer research #Cancer Research UK #CRISPR #Drug resistance #Gene editing #Genetic study #Stomach cancer #The Institute of Cancer Research

Study reveals how stomach cancers develop drug resistance

Scientists have shown how stomach cancers can develop resistance to a new class of drugs called ATR inhibitors by switching off the activity of two key genes – raising the possibility of outsmarting cancer by predicting drug resistance in advance.  The findings could pave the way for… Read More

#Cancer Research #News

Breast cancer
#Breast cancer #Breast Cancer Now #Cancer immunotherapy #Cancer research #King's College London #Oncology #The Institute of Cancer Research

Immune targets identified for chemo-resistant breast cancers

Researchers from King’s College London and The Institute of Cancer Research, London, have performed a deep dive into the different immune markers within tumour tissue and blood samples of early breast cancer patients whose cancer failed to respond to chemotherapy given to them prior to surgery. The research gives insight… Read More

#Cancer Research #News